Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced positive data from an initial clinical study of the company’s novel prostate cancer liquid biopsy. The non-invasive, RNA-based test demonstrated the potential to accurately predict high-grade prostate cancer by analyzing biomarkers on exosomal RNA (exoRNA) via a simple urine sample.